{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:06:15Z","timestamp":1760853975274,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40121-018-0197-y","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T07:59:00Z","timestamp":1522137540000},"page":"261-275","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8804-4897","authenticated-orcid":false,"given":"Li","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Eley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7637-9617","authenticated-orcid":false,"given":"Yash","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayu","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayo","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malaz","family":"AbuTarif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar","family":"Garimella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"issue":"S1","key":"197_CR1","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes CC, Hindman S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(S1):S45\u201357.","journal-title":"J Hepatol"},{"key":"197_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM199908193410802","volume":"341","author":"MJ Alter","year":"1999","unstructured":"Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556\u201362.","journal-title":"N Engl J Med"},{"key":"197_CR3","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1128\/AAC.01186-12","volume":"56","author":"F McPhee","year":"2012","unstructured":"McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56:5387\u201396.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"197_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/TCRM.S66731","volume":"26","author":"I Gentile","year":"2014","unstructured":"Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014;26(10):493\u2013504.","journal-title":"Ther Clin Risk Manag"},{"key":"197_CR5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:414\u201329.","journal-title":"Lancet"},{"key":"197_CR6","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jhep.2014.07.011","volume":"61","author":"JP Bronowicki","year":"2014","unstructured":"Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ, Bessone F, Martorell CT, et al. Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. J Hepatol. 2014;61:1220\u20137.","journal-title":"J Hepatol"},{"key":"197_CR7","doi-asserted-by":"crossref","unstructured":"Zeuli JD, Adie SK, Rizza SA, Temesgen Z. Drugs today (Barc), Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc). 2015;51(11):629\u201343.","DOI":"10.1358\/dot.2015.51.11.2414528"},{"issue":"1","key":"197_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1586\/17474124.2014.953930","volume":"9","author":"SS Yang","year":"2015","unstructured":"Yang SS, Kao JH. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Rev Gastroenterol Hepatol. 2015;9(1):9\u201320.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"12","key":"197_CR9","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40262-015-0299-6","volume":"54","author":"T Eley","year":"2015","unstructured":"Eley T, Garimella T, Li W, Bertz RJ. Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug\u2013drug interactions. Clin Pharmacokinet. 2015;54(12):1205\u201322.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"197_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/cpdd.52","volume":"2","author":"T Eley","year":"2013","unstructured":"Eley T, He B, Huang SP, Li W, Pasquinelli C, Rodrigues AD, Grasela DM, Bertz RJ. Pharmacokinetics of the NS3 protease inhibitor, Asunaprevir (ASV, BMS-650032), in phase I studies in subjects with or without chronic hepatitis C. Clin Pharmacol Drug Dev. 2013;2(4):316\u201327.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"197_CR11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40262-015-0299-6","volume":"54","author":"T Eley","year":"2015","unstructured":"Eley T, Garimella T, Li W, Bertz RJ. Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug\u2013drug interactions. Clin Pharmacokinet. 2015;54:1205\u201322.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"197_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/00498254.2015.1048487","volume":"46","author":"J Gong","year":"2016","unstructured":"Gong J, Eley T, He B, Arora V, Philip T, Jiang H, Easter J, Humphreys WG, Iyer RA, Li W. Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46(1):52\u201364.","journal-title":"Xenobiotica"},{"key":"197_CR13","first-page":"abstract no. 38","volume":"54","author":"T Eley","year":"2011","unstructured":"Eley T, Gardiner D, Persson A, He B, You X, Shah V, et al. Evaluation of drug interaction potential of the HCV protease inhibitor asunaprevir (ASV; BMS-650032) at 200\u00a0mg twice daily in metabolic cocktail and P-glycoprotein (P-gp) probe studies in healthy volunteers [abstract]. Hepatology. 2011;54:abstract no. 381.","journal-title":"Hepatology."},{"issue":"1","key":"197_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3851\/IMP2773","volume":"20","author":"T Eley","year":"2015","unstructured":"Eley T, He B, Chang I, Colston E, Child M, Bedford W, et al. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor. Antivir Ther. 2015;20(1):29\u201337.","journal-title":"Antivir Ther."},{"key":"197_CR15","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00228-013-1525-5","volume":"69","author":"PN Morcos","year":"2013","unstructured":"Morcos PN, Moreira SA, Brennan BJ, Blotner S, Shulman NS, Smith PF. Influence of chronic hepatitis C infection on Asunaprevir Preclinical and Clinical PK and Drug Interactions 1221 cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. Eur J Clin Pharmacol. 2013;69:1777\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"197_CR16","first-page":"1070A","volume":"56","author":"T Eley","year":"2012","unstructured":"Eley T, Chan P, Huang S, Wind-Rotolo M, Delmonte T, He B, et al. Asunaprevir in Japanese subjects in phase 2: exposure-safety versus US\/EU-based subjects and preliminary assessment of correlation with single nucleotide polymorphisms (SNPs) in liver uptake transporters. Hepatology. 2012;56(Suppl 1):1070A\u20131A.","journal-title":"Hepatology"},{"key":"197_CR17","unstructured":"Eley T, Chan P, Sverdlov O, He B, Bedford B, Kandoussi H, et al. Improved bioavailability and mitigated food effect for asunaprevir utilizing a lipid-based formulation: similar exposure with 100\u00a0mg twice-daily soft-gel capsule relative to 200\u00a0mg twice daily of phase 2 tablet [abstract\/poster no. A-1247]. In: 52nd Interscience conference antimicrobial agents chemotherapy. San Francisco; 9\u201312 Sep 2012."},{"key":"197_CR18","unstructured":"Marc Gastonguay. full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. Page 20 (2011) Abstr 2229. http:\/\/www.page-meeting.org\/?abstract=2229 . Accessed 21 Mar 2018."},{"issue":"1","key":"197_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","volume":"59","author":"J Parke","year":"1999","unstructured":"Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed. 1999;59(1):19\u201329.","journal-title":"Comput Methods Programs Biomed"},{"key":"197_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143.","journal-title":"AAPS J"},{"issue":"3","key":"197_CR21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558\u201369.","journal-title":"AAPS J"},{"issue":"Suppl 1","key":"197_CR22","doi-asserted-by":"publisher","first-page":"45S","DOI":"10.1046\/j.0306-5251.2001.00032.x","volume":"53","author":"PA Milligan","year":"2002","unstructured":"Milligan PA, Marshall SF, Karlsson MO. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol. 2002;53(Suppl 1):45S\u201352S.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"197_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-012-1300-z","volume":"69","author":"I Oteo","year":"2013","unstructured":"Oteo I, Lukas JC, Leal N. Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via bayesian prediction. Eur J Clin Pharmacol. 2013;69(1):65\u201374.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"197_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1389200043489054","volume":"5","author":"RH Elbekai","year":"2004","unstructured":"Elbekai RH, Korashy HM, El-Kadi AOS. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab. 2004;5(2):157\u201367.","journal-title":"Curr Drug Metab."},{"issue":"Suppl1","key":"197_CR25","doi-asserted-by":"publisher","first-page":"S328","DOI":"10.1016\/S0168-8278(13)60806-5","volume":"58","author":"P Chan","year":"2013","unstructured":"Chan P, et al. Exposure-response analyses of asunaprevir in combination with daclatasvir\u2009\u00b1\u2009peginterferon\/ribavirin among patients with genotype 1 chronic HCV infection: dose selection for phase 3 clinical trials. J Hepatol. 2013;58(Suppl1):S328\u20139.","journal-title":"J Hepatol"},{"issue":"10","key":"197_CR26","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1517\/14740338.2015.1084287","volume":"14","author":"I Gentile","year":"2015","unstructured":"Gentile I, Zappulo E, Buonomo AR, Scotto R, Borgia G. Asunaprevir for hepatitis C: a safety evaluation. Expert Opin Drug Saf. 2015;14(10):1631\u201346.","journal-title":"Expert Opin Drug Saf."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-018-0197-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40121-018-0197-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-018-0197-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T10:00:58Z","timestamp":1570960858000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-018-0197-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["197"],"URL":"https:\/\/doi.org\/10.1007\/s40121-018-0197-y","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2018,3,27]]},"assertion":[{"value":"15 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}